TY - JOUR T1 - Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma JF - In Vivo JO - In Vivo SP - 2793 LP - 2800 DO - 10.21873/invivo.12565 VL - 35 IS - 5 AU - TAKASHI NAGAI AU - TAKU NAIKI AU - TERUKI ISOBE AU - YOSUKE SUGIYAMA AU - TOSHIKI ETANI AU - KEITARO IIDA AU - SATOSHI NOZAKI AU - YUSUKE NODA AU - NOBUHIKO SHIMIZU AU - YOSHIHIKO TASAKI AU - YOSHIHISA MIMURA AU - RIKA BANNO AU - HIROKI KUBOTA AU - SHUZO HAMAMOTO AU - NORIYASU KAWAI AU - TAKAHIRO YASUI Y1 - 2021/09/01 UR - http://iv.iiarjournals.org/content/35/5/2793.abstract N2 - Background/Aim: Predicting the prognosis of metastatic urothelial carcinoma (mUC) patients is needed for clinical decisions. We examined the value of a modified Glasgow prognostic score (mGPS) as a predictive marker for mUC patients. Patients and Methods: In a multicenter study, 68 mUC patients received short hydration gemcitabine/cisplatin (shGC) and 74 received pembrolizumab (PEM). Patients were allocated according to mGPS. Progression-free (PFS) and cancer-specific (CSS) survival were examined. Results: Higher mGPS reflected poorer PFS and CSS in shGC (p=0.03, p<0.0001, respectively) and PEM (p=0.02, p<0.001, respectively) patients. PFS for the high mGPS group was longer than that of the low mGPS group in the two cohorts (p <0.0001 for both), with similar CSS results (p<0.0001 and p<0.001, respectively). Multivariate analyses revealed high mGPS was a risk factor for poor CSS in both cohorts (HR=3.55, p<0.001, and HR=2.21, p<0.01, respectively). Conclusion: In the mUC patients receiving shGC or PEM, mGPS was a predictive prognostic marker. ER -